<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">ATAZANAVIR</span><br/>(a-ta-zan'a-vir)<br/><span class="topboxtradename">Reyataz<br/></span><b>Classifications:</b> <span class="classification">anti-infective</span>; <span class="classification">antiviral agent</span>; <span class="classification">antiretroviral agent</span>; <span class="classification">protease inhibitor</span><br/><b>Prototype: </b>Saquinavir<br/><b>Pregnancy Category: </b>B<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>100 mg, 150 mg, 200 mg capsules</p>
<h1><a name="action">Actions</a></h1>
<p>Atazanavir is an HIV-1 protease inhibitor that selectively inhibits the replication of HIV. Protease plays a major role in
         the virus-specific processing of viral Gag and Gag-Pol gene products into key structural proteins and replication enzymes
         of HIV-1 needed in the replication process of HIV-1 infected cells. Thus, protease is necessary for the production of mature
         virions.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Protease inhibition renders the virus noninfectious. Because HIV protease inhibitors inhibit the HIV replication cycle after
         translation and before assembly, they are active in acutely and chronically infected cells. Thus, atazanavir reduces the viral
         load and increases CD4+ cell count.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Treatment of HIV infection in combination with other antiretroviral agents.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to atazanavir; severe hepatic insufficiency; lactation; concurrent administration of any of the following:
         rifampin, irinotecan, midazolam, triazolam, bepridil, dihydroergotamine, ergotamine, ergonovine, methylergonovine, lovastatin,
         simvastatin, pimozide, indinavir, St. John's wort; lactation; lactase deficiency.
      </p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Moderate hepatic impairment, hepatitis B or C; pregnancy (category B); neonates, infants, children; elderly, females, diabetes
         mellitus, diabetic ketoacidosis; hemophilia, hepatic disease; hepatitis; jaundice, hypercholesterolemia, hyperglycemia, hypertriglyceridemia;
         lactic acidosis, pancreatitis, obesity.
      </p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">HIV Infection (treatment-naïve)</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 400 mg once/d with a light meal<br/><br/><span class="indicationtitle">HIV Infection (treatment-experienced)</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 300 mg once/d plus 100 mg ritonavir with food<br/><br/><span class="impairmenttitle">Hepatic Impairment</span><br/>Reduce dose to 300 mg once/d in moderate hepatic insufficiency; not recommended for use in severe hepatic insufficiency<br/><br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Give with a light meal, not on an empty stomach.</li>
<li>When coadministered with efavirenz, give atazanavir 300 mg and ritonavir 100 mg with efavirenz 600 mg (all as a single daily
            dose with food). Atazanavir without ritonavir should not be coadministered with efavirenz.
         </li>
<li>When coadministered with didanosine buffered formulations, give atazanavir (with food) 2 h before or 1 h after didanosine.</li>
<li>Give 2 h before/1 h after antacids or buffered drugs.</li>
<li>Store at 15°30° C (59°86° F).</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">Body as a Whole:</span>
<span class="speceff-common">Peripheral neuropathy,</span> fever, pain, fatigue, allergic reaction, angioedema, asthenia, burning sensation, chest pain, edema, facial atrophy, generalized
      edema, heat sensitivity, infection, malaise, pallor, peripheral edema, photosensitivity, substernal chest pain, sweating. <span class="typehead">CNS:</span>
<span class="speceff-common">Headache,</span> depression, insomnia, dizziness, abnormal dream, abnormal gait, agitation, amnesia, anxiety, confusion, convulsion, decreased
      libido, emotional lability, hallucination, hostility, hyperkinesia, hypesthesia, increased reflexes, nervousness, psychosis,
      sleep disorder, somnolence, suicide attempt, twitch. <span class="typehead">CV:</span>
<span class="speceff-life">Cardiac arrest</span>, heart block (PR prolongation), hypertension, myocarditis, palpitation, syncope, vasodilatation. <span class="typehead">GI:</span> Hyperbilirubinemia, jaundice, <span class="speceff-common">nausea, vomiting, diarrhea,</span> abdominal pain, anorexia, aphthous stomatitis, colitis, constipation, dental pain, dyspepsia, enlarged abdomen, esophageal
      ulcer, esophagitis, flatulence, gastritis, gastroenteritis, gastrointestinal disorder, hepatitis, hepatomegaly, hepatosplenomegaly,
      increased appetite, liver damage, liver fatty deposit, mouth ulcer, pancreatitis, peptic ulcer. <span class="typehead">Endocrine:</span> Decreased male fertility. <span class="typehead">Hematologic:</span> Ecchymosis, purpura. <span class="typehead"> Metabolic:</span>  Lipodystrophy syndrome, hypercholesterolemia, hypertriglyceridemia. <span class="typehead">Musculoskeletal:</span> Myalgia, arthralgia. <span class="typehead">Respiratory:</span> Cough, dyspnea, hiccup. <span class="typehead">Skin:</span>
<span class="speceff-common">Rash,</span> alopecia, cellulitis, dermatophytosis, dry skin, eczema, nail disorder, pruritus, seborrhea, urticaria, vesiculobullous rash. <span class="typehead">Special Senses:</span> Otitis, taste perversion, tinnitus. <span class="typehead">Urogenital:</span> Abnormal urine, amenorrhea, crystalluria, gynecomastia, hematuria, impotence, kidney calculus, kidney failure, kidney pain,
      menstrual disorder, oliguria, pelvic pain, polyuria, proteinuria, urinary frequency, urinary tract infection. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead"> Drug:</span>  May increase levels and toxicity of <b>cyclosporine,</b> systemic <b>lidocaine, sirolimus, tacrolimus;</b> increase risk of myopathy and rhabdomyolysis with <b>atorvastatin, lovastatin, simvastatin;</b> may increase risk of heart block with <b>diltiazem;</b>
<span class="classification">antacids</span>, <span class="classification">h<sub>2</sub>-receptor antagonists</span>, <span class="classification">proton pump inhibitors</span> may decrease absorption of atazanavir; <b>ritonavir</b> may increase atazanavir levels; may increase toxicity of <b>irinotecan;</b> increased risk of prolonged sedations with <span class="classification">benzodiazepines</span>; <b>indinavir</b> may increase risk of hyperbilirubinemia; <b>didanosine, efavirenz, rifampin</b> may decrease atazanavir levels; <b>ergotamine, ergonovine dihydroergotamine, bepridil, pimozide</b> may cause serious adverse reactions; may increase risk of hypotension, visual changes, and priapism with <b>sildenafil, tadalafil, vardenafil.</b>
<span class="typehead">Herbal:</span>
<b>St. John's wort</b> may decrease atazanavir levels. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> 68% absorbed into systemic circulation; taking with food enhances bioavailability.  <span class="typehead">Peak:</span>  22.5 h. <span class="typehead">Metabolism:</span> Metabolized in liver by CYP3A4. <span class="typehead">Elimination:</span> 70% excreted in feces, 13% excreted in urine. <span class="typehead">Half-Life:</span> 7 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Monitor CV status and ECG closely, especially with concurrent treatment with other drugs known to prolong the PR interval.</li>
<li>Lab tests: Baseline and periodic LFTs; total bilirubin if jaundiced; periodic PT/INR with concurrent warfarin therapy; monitor
            blood glucose closely, especially if diabetic.
         </li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Do not alter the dose or discontinue therapy without consulting physician.</li>
<li>Inform physician of all prescription, nonprescription, or herbal meds being used.</li>
<li>Report promptly any of the following: dizziness or lightheadedness; muscle pain (especially with concurrent statin therapy);
            severe nausea, vomiting (especially if red or "coffee-ground" in appearance), stomach pain, black tarry stools; yellowing
            of skin or whites of eyes; skin rash or itchy skin; sore throat, fever, or other S&amp;S of infection; unexplained tiredness or
            weakness.
         </li>
<li>If taking both sildenafil and atazanavir, promptly report any of the following sildenafil-associated adverse effects: hypotension,
            visual changes, or prolonged penile erection.
         </li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>